ClinicalTrials.gg
TerminatedNCT03260868Updated Apr 7, 2022Results posted

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

A Phase 4 interventional study of Insulin glargine, 300 units per milliliter (U/mL) and Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra) in Type 1 Diabetes Mellitus, sponsored by Sanofi. Terminated at 6 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-07.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Why this study was terminated
Due to "prolonged low participant recruitment"

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.

Enrollment
64th of 66
15 · median 73
Started
2017
with 3 others
Phase 4
24 of 66
none open now
Registered
52nd of 66
by date
Lead sponsor
24 of 66
Sanofi

Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 64th largest by enrollment, is one of 4 that started in 2017, is one of 24 in phase 4, and was the 52nd registered.

Diabetes Mellitus, Type 1

3,754 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

Primary Objective:

To evaluate the effect of virtual approach via novel technologies versus traditional study conduct on glycemic control in terms of glycated hemoglobin (HbA1c).

Secondary Objective:

To evaluate the appropriate utilization of virtual approach via novel technologies during the study and to assess the effect of the virtual versus traditional study conduct on multiple outcomes in terms of study methodology and diabetes management.

Read the detailed description

The study had a maximum study duration of 29 weeks, which consisted of a 3-week screening period (including a possible 1-week delay in first investigational medicinal product [IMP] administration after randomization in virtual group due to shipment of IMP and the virtual devices), a 24-week treatment period, and 1-week post-treatment safety follow-up period.

03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with Type 1 diabetes mellitus (T1DM) diagnosed at least one year before the screening visit.
  • Participants who were treated with multi-dose insulin using insulin glargine 100 U/mL (eg, Lantus or Basaglar) as basal insulin and rapid acting insulin analogues as bolus insulin.
  • Participants with access to or experience with mobile technology (eg, tablet or smart phone).
  • eSign the consent on the study web portal.

Exclusion criteria

Exclusion criteria:

  • Age less than (\<) 18 years at screening (Visit 1 - Step 1).
  • Type 2 diabetes mellitus.
  • \<5.4 percent (%) or greater than or equal to (>=) 9.0% measured by the central lab at Visit 1.
  • Participants who received \<6 months treatment with any basal plus (+) meal-time insulin.
  • Use of any basal insulins other than insulin glargine 100 U/mL (eg, Lantus or Basaglar) within 3 months before screening.
  • Use of an insulin pump within 6 months before screening.
  • Use of meal-time insulin other than rapid-acting insulin analogs (Humalog, Novolog, or Apidra), eg, human regular insulin, within 30 days before screening.
  • Hemoglobinopathy resulting in undetectable HbA1c by the central laboratory, or hemolytic anemia requiring transfusion of blood or plasma products within 3 months before screening.
  • Participants experienced with any severe hypoglycemic episode resulting in seizure, unconsciousness, or coma, and/or leading to hospitalization during the past 6 months before screening.
  • Participants with insufficient smart phone skills or unwilling to properly use the virtual tools deemed by the investigator based on the observation and experiences over the digital screening procedure-Mental disorders or any neurologic disorder that would affect participant's ability to meet the study requirements, or participants deemed unlikely to safely manage insulin dosage by the investigator.
  • Known /intolerance to insulin glargine, rapid-acting insulin analogs or any of their .
  • Pregnant or breast-feeding women, or women who intend to become pregnant during the study period.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Virtual

    Participants included in this virtual trial approach group did not visit the study sites during the study course. All study assessments, including vital signs, weight, laboratory variables, etc., were completed via the Bluetooth devices that instantly transfer the digital data.

    Drug: Insulin glargine, 300 units per milliliter (U/mL) · Drug: Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)

  • Active comparator
    Traditional

    Participants included in this traditional trial approach group visited the study site, followed the study visit schedules for all study assessments that was performed either in-person or phone visits.

    Drug: Insulin glargine, 300 units per milliliter (U/mL) · Drug: Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)

Interventions

  • DrugInsulin glargine, 300 units per milliliter (U/mL)

    Drug page: Insulin Glargine

    Self-administered subcutaneous injection using prefilled pen once daily for 24 weeks. Dose titration to achieve fasting self-monitoring of plasma glucose (SMPG) level between 80 and 130 milligram per deciliter (mg/dL).

    Also known as: Toujeo ®

  • DrugBackground therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)

    Subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Glycated Hemoglobin A1c (HbA1c) to Week 24

    Change in HbA1c was calculated by subtracting baseline value from Week 24 value.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Change From Baseline in Glycated Hemoglobin A1c to Week 16

    Change in HbA1c was calculated by subtracting baseline value from Week 16 value.

    Time frame: Baseline, Week 16

  2. Change From Baseline in Fasting Plasma Glucose (FPG) to Week 16 and Week 24

    Change in FPG was calculated by subtracting baseline value from Week 16 value (for change at Week 16) and Week 24 (for change at Week 24) value.

    Time frame: Baseline, Week 16, Week 24

  3. Participant Satisfaction With Trial Experience: Was It Worth It (WIWI) Questionnaire Response at Week 24

    Participant satisfaction with trial experience was measured using the WIWI questionnaire. The WIWI had 5 questions, 3 questions with level categorical response (Yes, No, and Unsure) scale, 1 question with 3 possible answers as: Better than I expected/The same as I expected/Worse than I expected, and 1 question with 3 possible answers: It improved/Stayed the same/Become worse.

    Time frame: At Week 24

  4. Change From Baseline in Work Productivity and Impairment-Study Participation (WPAI-SP) Scores to Week 24

    Effect of trial on a participants' ability to work and perform regular activities were measured using WPAI-SP. WPAI-SP had 6 items scored separately, where higher score indicated greater impairment and less productivity.

    Time frame: Baseline, Week 24

  5. Change From Baseline in Overall Study Experience-Participation (OSEP) Part-1 Questionnaire Score to Week 24

    Participant burden with trial participation was measured using the OSEP Questionnaire, administered electronically. OSEP Part-1 contained 4 items to examine perceptions of study participation. Each item was measured on an 11 point scale ranged from 0 (completely disagree) to 10 (completely agree), where higher score indicated higher perception of diabetes control.

    Time frame: Baseline, Week 24

  6. Change From Baseline in Overall Study Experience-Participation Part-2 Questionnaire Score to Week 24

    Participant burden with trial participation was measured using the OSEP Questionnaire, administered electronically. OSEP Part-2 contained 9 items to examine perceptions of study participation. Each item was measured on an 11 point scale ranged from 0 (completely disagree) to 10 (completely agree), where higher score indicated higher burden with trial participation.

    Time frame: Baseline, Week 24

  7. Resource Use Questionnaire (RUQ) Scores

    Healthcare resource use was measured using the RUQ which asked participants to report the resources used (time and expenses) during the previous 4 weeks in terms of visits to healthcare professionals.

    Time frame: During 24 weeks treatment period

  8. Change From Baseline in Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) to Week 24

    The DTSQs was a validated questionnaire to assess participant's satisfaction with their diabetes treatment. It consisted of 8 items that were answered on a Likert scale from 0 (no satisfaction) to 6 (high satisfaction with treatment). Total treatment satisfaction score was the sum of items 1, 4-8 scores and ranged from 0 (no satisfaction) to 36 (high satisfaction with treatment).

    Time frame: Baseline, Week 24

  9. Change From Baseline in Diabetes Treatment Satisfaction Questionnaire Change (DTSQc) Score to Week 24

    DTSQc measured the relative change in treatment satisfaction from previous therapy. It consists of 8 items that were answered on a 6 point scale ranges from 3 (much less satisfied) to -3 (much more satisfied). Total treatment satisfaction score was the sum of items 1, 4-8 scores and ranged from -18 (much less satisfied) to +18 (much more satisfied), higher score indicated more satisfaction.

    Time frame: Baseline, Week 24

  10. Hypoglycemia Fear Survey-II (HFS-II) Scores

    Fear of hypoglycemia was measured with HFS-II at Week 24. The HFS-II comprises 33 items: 15 items explore behaviors that participants were engaged in to avoid low blood sugar and its negative consequences and 18 items related to concern/worry that participants had about their hypoglycemia. Responses to each item were made on a 5-point Likert scale ranges from 0 equal (=) "Never" to 4 = "Always". Total HFS mean score was determined by computing the mean of all 33 items and the score ranged from 0 to 4, where higher score indicated more fear/worry.

    Time frame: At Week 24

  11. Diabetes Distress Scale (DDS) Scores

    Diabetes-related distress was measured using DDS. The DDS contained 17 items related to potential problem areas that people with diabetes may experience. Participants were asked to consider the degree to which each of the items might have distressed or bothered them during the past month, and respond for each item on a 7 point scale ranges from 1 (not a problem) to 6 (a very serious problem), higher score indicated more diabetes related distress.

    Time frame: Week 0, Week 24

  12. Change From Baseline in 7-Point Self-Monitoring of Plasma Glucose (SMPG) Profiles at Week 16 and Week 24 Per Time Point

    7-point SMPG profiles were measured at the following 7 points at each visit (Baseline, Week 16, and Week 24): before breakfast, 2 hours after breakfast, before lunch, 2 hours after lunch, before dinner, 2 hours after dinner, and bedtime. For each time point, the value at each visit was calculated as the average of values obtained for the same time point across profiles performed in the week before the visit.

    Time frame: Baseline, Week 16, Week 24

  13. Average Daily Insulin Doses

    Average daily insulin doses included basal insulin doses, mealtime insulin doses, and total insulin doses.

    Time frame: During 24 weeks treatment period

  14. Overall Study Experience-Sites (OSES) Questionnaire Part-1: Hours Spent by Investigator

    An OSES questionnaire was completed by Site Investigator and had 2 parts. The OSES Part-1 contained quantitative 1 item (question) to examine resource requirements which was: Approximately how much time did you spend with this participant (in person or via phone) during this scheduled visit/communication? (hours)

    Time frame: During 24 weeks treatment period

  15. Overall Study Experience-Sites Questionnaire Part-2 Scores for Site-Perceived Participant Relationship and Satisfaction at Week 24

    An OSES questionnaire was completed by site investigator and had two parts. OSES Part-2 contains 2 items to examine investigator-participant relationship and satisfaction with care. Both items were assessed on a scale of 0 \[completely disagree\] to 10 \[completely agree\]), where highest score indicated a good relationship and satisfaction with care.

    Time frame: At Week 24

  16. Number of Participants With At Least One Hypoglycemic Events (Any, Severe Documented Symptomatic, Probable Symptomatic, Asymptomatic, Pseudo-hypoglycemia: Any Time of the Day) During 24 Week Treatment Period

    Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycemia: an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<=3.9 mmol/L (70 mg/dL) or \<3.0 mmol/L (54 mg/dL). Asymptomatic hypoglycemia: an event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration \<=3.9 mmol/L (70 mg/dL) or \<3.0 mmol/L (54 mg/dL). Probable symptomatic hypoglycemia: an event during which symptoms of hypoglycemia were not accompanied by plasma glucose determination but was presumably caused by a plasma glucose concentration. Pseudo-hypoglycemia: an event with any of the typical symptoms of hypoglycaemia with plasma glucose concentration \>3.9 mmol/L (70 mg/dL).

    Time frame: During 24 weeks treatment period

07

Results

Posted Jan 7, 2020
Limitations and caveats
Planned analysis could not be performed due to early study termination.

Participant flow

Participants were enrolled in the study at 6 sites in Canada and United States between 19 September 2017 and 02 October 2018.

Participant flow — Overall Study
MilestoneVirtualTraditional
Started87
Safety population86
Completed54
Not completed33
Withdrew: Poor compliance to protocol02
Withdrew: Study terminated by sponsor21
Withdrew: Other than specified above10

Outcome measures

PrimaryChange From Baseline in Glycated Hemoglobin A1c (HbA1c) to Week 24

Change in HbA1c was calculated by subtracting baseline value from Week 24 value.

Time frame:
Baseline, Week 24
Reported as:
Mean · percentage of HbA1c
Change From Baseline in Glycated Hemoglobin A1c (HbA1c) to Week 24
percentage of HbA1cVirtualTraditional
Change From Baseline in Glycated Hemoglobin A1c (HbA1c) to Week 240.10 ± 0.760.33 ± 0.57
SecondaryChange From Baseline in Glycated Hemoglobin A1c to Week 16

Change in HbA1c was calculated by subtracting baseline value from Week 16 value.

Time frame:
Baseline, Week 16
Reported as:
Mean · percentage of HbA1c
Change From Baseline in Glycated Hemoglobin A1c to Week 16
percentage of HbA1cVirtualTraditional
Change From Baseline in Glycated Hemoglobin A1c to Week 160.23 ± 0.520.45 ± 0.13
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) to Week 16 and Week 24

Change in FPG was calculated by subtracting baseline value from Week 16 value (for change at Week 16) and Week 24 (for change at Week 24) value.

Time frame:
Baseline, Week 16, Week 24
Reported as:
Mean · millimole per liter (mmol/L)
Change From Baseline in Fasting Plasma Glucose (FPG) to Week 16 and Week 24
millimole per liter (mmol/L)VirtualTraditional
Week 16-0.660 ± 2.387-0.200 ± 4.555
Week 24-3.625 ± 3.4062.900 ± 1.758
SecondaryParticipant Satisfaction With Trial Experience: Was It Worth It (WIWI) Questionnaire Response at Week 24

Participant satisfaction with trial experience was measured using the WIWI questionnaire. The WIWI had 5 questions, 3 questions with level categorical response (Yes, No, and Unsure) scale, 1 question with 3 possible answers as: Better than I expected/The same as I expected/Worse than I expected, and 1 question with 3 possible answers: It improved/Stayed the same/Become worse.

Time frame:
At Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in Work Productivity and Impairment-Study Participation (WPAI-SP) Scores to Week 24

Effect of trial on a participants' ability to work and perform regular activities were measured using WPAI-SP. WPAI-SP had 6 items scored separately, where higher score indicated greater impairment and less productivity.

Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in Overall Study Experience-Participation (OSEP) Part-1 Questionnaire Score to Week 24

Participant burden with trial participation was measured using the OSEP Questionnaire, administered electronically. OSEP Part-1 contained 4 items to examine perceptions of study participation. Each item was measured on an 11 point scale ranged from 0 (completely disagree) to 10 (completely agree), where higher score indicated higher perception of diabetes control.

Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in Overall Study Experience-Participation Part-2 Questionnaire Score to Week 24

Participant burden with trial participation was measured using the OSEP Questionnaire, administered electronically. OSEP Part-2 contained 9 items to examine perceptions of study participation. Each item was measured on an 11 point scale ranged from 0 (completely disagree) to 10 (completely agree), where higher score indicated higher burden with trial participation.

Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

SecondaryResource Use Questionnaire (RUQ) Scores

Healthcare resource use was measured using the RUQ which asked participants to report the resources used (time and expenses) during the previous 4 weeks in terms of visits to healthcare professionals.

Time frame:
During 24 weeks treatment period

No measurements were reported for this outcome.

SecondaryChange From Baseline in Diabetes Treatment Satisfaction Questionnaire Status (DTSQs) to Week 24

The DTSQs was a validated questionnaire to assess participant's satisfaction with their diabetes treatment. It consisted of 8 items that were answered on a Likert scale from 0 (no satisfaction) to 6 (high satisfaction with treatment). Total treatment satisfaction score was the sum of items 1, 4-8 scores and ranged from 0 (no satisfaction) to 36 (high satisfaction with treatment).

Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in Diabetes Treatment Satisfaction Questionnaire Change (DTSQc) Score to Week 24

DTSQc measured the relative change in treatment satisfaction from previous therapy. It consists of 8 items that were answered on a 6 point scale ranges from 3 (much less satisfied) to -3 (much more satisfied). Total treatment satisfaction score was the sum of items 1, 4-8 scores and ranged from -18 (much less satisfied) to +18 (much more satisfied), higher score indicated more satisfaction.

Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

SecondaryHypoglycemia Fear Survey-II (HFS-II) Scores

Fear of hypoglycemia was measured with HFS-II at Week 24. The HFS-II comprises 33 items: 15 items explore behaviors that participants were engaged in to avoid low blood sugar and its negative consequences and 18 items related to concern/worry that participants had about their hypoglycemia. Responses to each item were made on a 5-point Likert scale ranges from 0 equal (=) "Never" to 4 = "Always". Total HFS mean score was determined by computing the mean of all 33 items and the score ranged from 0 to 4, where higher score indicated more fear/worry.

Time frame:
At Week 24

No measurements were reported for this outcome.

SecondaryDiabetes Distress Scale (DDS) Scores

Diabetes-related distress was measured using DDS. The DDS contained 17 items related to potential problem areas that people with diabetes may experience. Participants were asked to consider the degree to which each of the items might have distressed or bothered them during the past month, and respond for each item on a 7 point scale ranges from 1 (not a problem) to 6 (a very serious problem), higher score indicated more diabetes related distress.

Time frame:
Week 0, Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in 7-Point Self-Monitoring of Plasma Glucose (SMPG) Profiles at Week 16 and Week 24 Per Time Point

7-point SMPG profiles were measured at the following 7 points at each visit (Baseline, Week 16, and Week 24): before breakfast, 2 hours after breakfast, before lunch, 2 hours after lunch, before dinner, 2 hours after dinner, and bedtime. For each time point, the value at each visit was calculated as the average of values obtained for the same time point across profiles performed in the week before the visit.

Time frame:
Baseline, Week 16, Week 24

No measurements were reported for this outcome.

SecondaryAverage Daily Insulin Doses

Average daily insulin doses included basal insulin doses, mealtime insulin doses, and total insulin doses.

Time frame:
During 24 weeks treatment period

No measurements were reported for this outcome.

SecondaryOverall Study Experience-Sites (OSES) Questionnaire Part-1: Hours Spent by Investigator

An OSES questionnaire was completed by Site Investigator and had 2 parts. The OSES Part-1 contained quantitative 1 item (question) to examine resource requirements which was: Approximately how much time did you spend with this participant (in person or via phone) during this scheduled visit/communication? (hours)

Time frame:
During 24 weeks treatment period

No measurements were reported for this outcome.

SecondaryOverall Study Experience-Sites Questionnaire Part-2 Scores for Site-Perceived Participant Relationship and Satisfaction at Week 24

An OSES questionnaire was completed by site investigator and had two parts. OSES Part-2 contains 2 items to examine investigator-participant relationship and satisfaction with care. Both items were assessed on a scale of 0 \[completely disagree\] to 10 \[completely agree\]), where highest score indicated a good relationship and satisfaction with care.

Time frame:
At Week 24

No measurements were reported for this outcome.

SecondaryNumber of Participants With At Least One Hypoglycemic Events (Any, Severe Documented Symptomatic, Probable Symptomatic, Asymptomatic, Pseudo-hypoglycemia: Any Time of the Day) During 24 Week Treatment Period

Severe hypoglycemia was an event in which the participant required the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Documented symptomatic hypoglycemia: an event during which typical symptoms of hypoglycemia were accompanied by a measured plasma glucose concentration of \<=3.9 mmol/L (70 mg/dL) or \<3.0 mmol/L (54 mg/dL). Asymptomatic hypoglycemia: an event not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose concentration \<=3.9 mmol/L (70 mg/dL) or \<3.0 mmol/L (54 mg/dL). Probable symptomatic hypoglycemia: an event during which symptoms of hypoglycemia were not accompanied by plasma glucose determination but was presumably caused by a plasma glucose concentration. Pseudo-hypoglycemia: an event with any of the typical symptoms of hypoglycaemia with plasma glucose concentration \>3.9 mmol/L (70 mg/dL).

Time frame:
During 24 weeks treatment period
Reported as:
Count of participants · Participants
Number of Participants With At Least One Hypoglycemic Events (Any, Severe Documented Symptomatic, Probable Symptomatic, Asymptomatic, Pseudo-hypoglycemia: Any Time of the Day) During 24 Week Treatment Period
ParticipantsVirtualTraditional
Any hypoglycemia73
Severe hypoglycemia00
Documented symptomatic hypoglycemia: <=3.9 mmol/L63
Documented symptomatic hypoglycemia: <3.0 mmol/L43
Probable symptomatic hypoglycemia00
Asymptomatic hypoglycemia <=3.9 mmol/L43
Asymptomatic hypoglycemia <3.0 mmol/L11
Pseudo-hypoglycemia >3.9 mmol/L10

Adverse events

Collected over All Adverse Events (AEs) were collected from time of first dose of study drug up to 25 weeks regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Virtual0/8 (0%)1/8 (12.5%)2/8 (25%)
Traditional0/6 (0%)1/6 (16.7%)4/6 (66.7%)
Most frequent serious events
Most frequent serious events
EventVirtualTraditional
Loss Of ConsciousnessNervous system disorders0/81/6
Obstructive PancreatitisGastrointestinal disorders1/80/6
Cholecystitis AcuteHepatobiliary disorders1/80/6
Escherichia BacteraemiaInfections and infestations1/80/6
Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders1/80/6
Most frequent other events
Showing 10 of 12
Most frequent other events
EventVirtualTraditional
NasopharyngitisInfections and infestations0/82/6
DiarrhoeaGastrointestinal disorders0/81/6
Oedema PeripheralGeneral disorders0/81/6
Gastroenteritis ViralInfections and infestations0/81/6
Upper Respiratory Tract InfectionInfections and infestations1/81/6
Alcohol PoisoningInjury, poisoning and procedural complications0/81/6
Head InjuryInjury, poisoning and procedural complications0/81/6
Intervertebral Disc DegenerationMusculoskeletal and connective tissue disorders0/81/6
Vertebral OsteophyteMusculoskeletal and connective tissue disorders0/81/6
CholelithiasisHepatobiliary disorders1/80/6

Baseline characteristics

Analysis was performed on randomized population which included any participant who was allocated to a study conduct approach group regardless of whether the study conduct approach group was followed.

Age, Continuous
Age, Continuous(years)VirtualTraditionalTotal
Mean53.1 ± 5.645.6 ± 14.349.6 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)VirtualTraditionalTotal
Female202
Male6713
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VirtualTraditionalTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White8715
More than one race000
Unknown or Not Reported000
Body mass index (BMI)
Body mass index (BMI)(kilogram per meter square (kg/m^2))VirtualTraditionalTotal
Mean38.2 ± 18.430.9 ± 4.134.8 ± 13.8
Duration of Type 1 Diabetes
Duration of Type 1 Diabetes(years)VirtualTraditionalTotal
Mean32.4 ± 11.519.3 ± 12.726.3 ± 13.4
08

Study locations

6 sites
  • Investigational Site Number 8400002
    West Des Moines, Iowa 50265, United States
  • Investigational Site Number 8400004
    Houston, Texas 77043, United States
  • Investigational Site Number 8400003
    Bridgeport, West Virginia 26330, United States
  • Investigational Site Number 1240001
    Barrie, L4M 7G1, Canada
  • Investigational Site Number 1240003
    Oakville, L6M 1M1, Canada
  • Investigational Site Number 1240002
    Thornhill, L4J 8L7, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Nov 2018, 14 months.

Results were first posted in Jan 2020, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2017
First posted
Aug 24, 2017
StartActual
Sep 19, 2017
Primary completionActual
Nov 22, 2018
CompletionActual
Nov 22, 2018
Results first posted
Jan 7, 2020
Last update
Apr 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03260868
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 24, 2017
Start date
Sep 19, 2017
Primary completion
Nov 22, 2018
Completion
Nov 22, 2018
Results posted
Jan 7, 2020
Last update
Apr 7, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion